Clinical Overview
Gabapentin is an anticonvulsant medication indicated for partial seizures and postherpetic neuralgia. Despite structural similarity to GABA, it does not directly interact with GABA receptors but modulates calcium channels to reduce neuronal excitability. It has extensive off-label use for various neuropathic pain conditions.
Primary Clinical Applications
Gabapentin is effective as adjunctive therapy for partial seizures in adults and children over 3 years. It is also FDA-approved for postherpetic neuralgia and has widespread off-label use for diabetic neuropathy, fibromyalgia, and other chronic pain conditions.
Mechanism and Pharmacokinetics
Gabapentin binds to voltage-gated calcium channels, reducing calcium influx and neurotransmitter release. It has nonlinear pharmacokinetics due to saturable absorption, requiring dose titration for optimal efficacy. The medication is not metabolized and is eliminated unchanged by the kidneys.
Clinical Advantages
Gabapentin has minimal drug interactions and does not require therapeutic drug monitoring. It is generally well-tolerated with a favorable safety profile, making it suitable for long-term use in chronic conditions.
Prescribing Information
Dosing & Administration
Epilepsy – Adults and Children >12 years:
- Initial: 300 mg 3 times daily
- Titration: Increase by 300 mg every 1-7 days
- Maintenance: 900-1800 mg daily in 3 divided doses
- Maximum: 3600 mg daily
Postherpetic Neuralgia:
- Day 1: 300 mg once daily
- Day 2: 300 mg twice daily
- Day 3: 300 mg 3 times daily
- Titrate: Up to 1800 mg daily in 3 divided doses
Pediatric Epilepsy (3-11 years):
- Starting dose: 10-15 mg/kg/day in 3 divided doses
- Effective dose: 25-35 mg/kg/day
Indications
- Adjunctive therapy for partial seizures (adults and children ≥3 years)
- Postherpetic neuralgia in adults
- Off-label: Diabetic neuropathy, fibromyalgia, restless leg syndrome
Contraindications
- Hypersensitivity to gabapentin or any component
- No absolute contraindications
Warnings & Precautions
- Suicidal thoughts: Monitor for behavioral changes
- Withdrawal seizures: Taper gradually when discontinuing
- Respiratory depression: Risk increased with CNS depressants
- Dizziness and somnolence: May impair driving ability
- Peripheral edema and weight gain
Drug Interactions
- Antacids: Reduce gabapentin absorption (separate by 2 hours)
- Morphine: Increased gabapentin levels
- CNS depressants: Enhanced sedation
- Hydrocodone: Increased exposure to both drugs
Adverse Reactions
Common (>10%):
- Dizziness, somnolence, peripheral edema
Neurological:
- Ataxia, fatigue, nystagmus, tremor
Other:
- Weight gain, blurred vision, dry mouth
Special Populations
- Renal Impairment: Dose adjustment required based on creatinine clearance
- Hemodialysis: Supplemental dose needed after dialysis
- Elderly: Start with lower doses due to decreased renal function
- Pregnancy: Category C – use if benefits outweigh risks
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
